Literature DB >> 22824736

Internet highs--seizures after consumption of synthetic cannabinoids purchased online.

Babak Tofighi1, Joshua D Lee.   

Abstract

BACKGROUND: Since 2004, a new wave of synthetic cannabinoids (SCs) known as "Spice drugs" has come under scrutiny because of their suspected link to neurological and psychiatric sequelae. These "herbal incense" or "potpourri blends" have gained popularity as a result of being more potent than natural cannabinoids, are not detected with current screening tests, and are easily modified by manufacturers to bypass legal restrictions. Unfortunately, cases of withdrawal phenomena, nausea, hypertension, and psychosis are now being reported in the medical literature. In addition, after reports in lay media of seizures and coma attributed to the consumption of the drug, anecdotal reports have emerged of similar findings in the medical literature. CASE DESCRIPTION: We report on a 48-year-old man who, after consuming the herbal blend, lost consciousness and suffered several episodes of seizures. Despite a complicated ICU stay, the patient recovered well with no subsequent neurological sequelae.
CONCLUSIONS: The authors interpreted the history and findings consistent with the consumption of a large amount of synthetic cannabinoids leading to new-onset seizures and coma. However, at the time of admission, the lack of routine laboratory testing and treatment options delayed the diagnosis and delivery of appropriate therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22824736     DOI: 10.1097/ADM.0b013e3182619004

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  22 in total

Review 1.  Synthetic cannabinoids 2015: An update for pediatricians in clinical practice.

Authors:  Daniel Castellanos; Leonard M Gralnik
Journal:  World J Clin Pediatr       Date:  2016-02-08

Review 2.  The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.

Authors:  Lisa K Brents; Paul L Prather
Journal:  Drug Metab Rev       Date:  2013-09-24       Impact factor: 4.518

3.  Medical Marijuana for Epilepsy?

Authors:  Murali K Kolikonda; Kavitha Srinivasan; Manasa Enja; Vishwanath Sagi; Steven Lippmann
Journal:  Innov Clin Neurosci       Date:  2016-04-01

4.  Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice.

Authors:  Michael B Gatch; Michael J Forster
Journal:  Behav Pharmacol       Date:  2014-12       Impact factor: 2.293

5.  Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA.

Authors:  Kevin G Shanks; William Clark; George Behonick
Journal:  J Anal Toxicol       Date:  2016-01-10       Impact factor: 3.367

6.  A survey of synthetic cannabinoid consumption by current cannabis users.

Authors:  Erik W Gunderson; Heather M Haughey; Nassima Ait-Daoud; Amruta S Joshi; Carl L Hart
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

7.  Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22.

Authors:  George Behonick; Kevin G Shanks; Dennis J Firchau; Gagan Mathur; Charles F Lynch; Marcus Nashelsky; David J Jaskierny; Chady Meroueh
Journal:  J Anal Toxicol       Date:  2014-05-29       Impact factor: 3.367

8.  Increases in synthetic cannabinoids-related harms: Results from a longitudinal web-based content analysis.

Authors:  Francois R Lamy; Raminta Daniulaityte; Ramzi W Nahhas; Monica J Barratt; Alan G Smith; Amit Sheth; Silvia S Martins; Edward W Boyer; Robert G Carlson
Journal:  Int J Drug Policy       Date:  2017-06-01

9.  High times, low sats: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use.

Authors:  Sameir Alhadi; Anupama Tiwari; Rais Vohra; Roy Gerona; Janak Acharya; Kathryn Bilello
Journal:  J Med Toxicol       Date:  2013-06

Review 10.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.